Sio Gene Therapies Inc Stock News

Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Announces Positive Phase 1 Data For Anktiva In HIV ImmunityBio, Inc. (NASDAQ: IBRX) announ

Sio Gene Therapies Inc (NASDAQ: SIOX ) has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson''s disease. Due to several factors, the Company is deprioritizing its Parkinson''s disease program, including resource requirements, development timelines to reach meaningful value inflection, and a challenging market and regulatory environment. Sio Full story available on Benzinga.com

Sio Gene Therapies Inc  SIOX has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson's disease. [LIVE NOW ON YOU

Sio Gene Therapies (SIOX) is trading ~10% lower in the post-market after announcing the resignation of its CEO, Dr. Pavan Cheruvu.Dr

– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease,

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

Sio Gene Therapies Inc (SIOX) shares closed today 14.0% higher than it did at the end of yesterday. The stock is currently flat year-to-date, down 53.6% over the past 12 months, and down 89.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $1.52 and as low as $1.27 this week.Shares closed 59.2% below its 52-week high and 15.7% above its 52-week low.Trading volume this week was 1.1% higher than the 10-day average and 25.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -100.0% The company's stock price performance over the past 12 months lags the peer average by 515.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SIOX made stellar progress in 2021.

Shares of Sio Gene Therapies Inc. (NASDAQ:SIOX) have earned a consensus rating of Buy from the seven brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12 month target price among brokerages []

Sio Gene Therapies Inc. (NASDAQ:SIOX)s traded shares stood at 0.48 million during the last session, with the companys beta value hitting 1.57. At the close of trading, the stocks price was $1.40, to imply a decrease of -4.11% or -$0.06 in intraday trading. The SIOX shares 52-week high remains $4.15, putting it -196.43% down since Sio Gene Therapies Inc. (NASDAQ: SIOX) Has Succeeded To Excite In 2021, The Stock Is Down -49.64% Year-To-Date Read More »

Sio Gene Therapies Inc. (NASDAQ:SIOX) concluded the trading at $1.41 on Friday, December 03 with a fall of -5.37% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $1.49 and 5Y monthly beta was reading 1.75 with its price kept floating in New Insight On Sio Gene Therapies Inc. (SIOX) Read More »

Charles Schwab Investment Management Inc. acquired a new position in Sio Gene Therapies Inc. (NASDAQ:SIOX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 20,023 shares of the companys stock, valued at approximately $55,000. Several other hedge funds have also recently added to or reduced []

Cubist Systematic Strategies LLC cut its position in Sio Gene Therapies Inc. (NASDAQ:SIOX) by 74.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,452 shares of the companys stock after selling 80,798 shares during the quarter. Cubist Systematic Strategies LLCs holdings []

Sio Gene Therapies Inc. (NASDAQ:SIOX) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 2.50% to the previous days close as strong demand from buyers drove the stock to $1.64. Actively observing the price movement in the last trading, the stock closed the session at $1.60, falling within a range of Sio Gene Therapies Inc. (NASDAQ:SIOX) Will Likely Reach 10.00 USD! Read More »